PA
ASND icon

Perceptive Advisors’s Ascendis Pharma A/S ASND Stock Holding History

Perceptive Advisors’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-200,000
Closed -$25K – 109
2019
Q1 		$25K Buy
+200,000
New +$17.5M ﹤0.01% 103

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Perceptive Advisors's ASND Position: Q2 2026 in Review

Perceptive Advisors reduced its Ascendis Pharma A/S (ASND) stake by 24% in Q2 2026, selling an estimated $85.9M and leaving 1,163,721 shares worth $310M. The position accounts for 4.66% of the portfolio, ranked #4.

Perceptive Advisors first reported a position in ASND in Q1 2015 and has held it in 14 quarters since. The position peaked at $350M in Q1 2026. 312 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

  • Perceptive Advisors held 1,163,721 shares of Ascendis Pharma A/S worth $310M as of Q2 2026.
  • Perceptive Advisors sold 367,700 Ascendis Pharma A/S shares in Q2 2026, an estimated $85.9M.
  • Ascendis Pharma A/S made up 4.66% of Perceptive Advisors's portfolio in Q2 2026, its #4 holding.
  • Perceptive Advisors first reported a position in Ascendis Pharma A/S in Q1 2015 and has held it in 14 quarters since.
  • Perceptive Advisors's Ascendis Pharma A/S position peaked at $350M in Q1 2026.
  • 312 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Perceptive Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.